What are the current treatment recommendations and unmet needs in early RRMM?

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.The Multiple Myeloma Hub was pleased to speak with Rahul Banerjee, Fred Hutchinson Cancer Research Center, Seattle, US. We asked about the current treatment recommendations and unmet needs in early relapsed/refractory multiple myeloma (RRMM). In this interview, Banerjee evaluates the latest advancements and unmet needs in the treatment of early RRMM, highlighting the approval of chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies for early relapse as major developments. Banerjee also discusses the challenges of identifying patients at risk for early relapse and assesses the potential for emerging therapies, such as antibody–drug conjugates, for all patients, but particularly those who may not have access to CAR T-cell therapies. Hosted on Acast. See acast.com/privacy for more information.